
GILEAD Oncology

# **ELEVATE Head and Neck Cancer: A Phase 2 Study of Magrolimab Combination Therapy in Patients With** Head and Neck Squamous Cell Carcinoma



<sup>a</sup>Once the Phase 2 Cohort 1 enrolls 20 patients in each Arm A and Arm B, Arm C (n=46) will open. Randomization will continue 1:1:1 across all 3 arms. 5-FU, fluorouracil; CPS, combined positive score; HNSCC, head and neck squamous cell carcinoma; PD-L1, programmed death-ligand 1.

# Key Eligibility Criteria<sup>1,2</sup>

#### **Key Inclusion Criteria**

#### All Patients

- · Histologically or cytologically confirmed metastatic or locally recurrent HNSCC that is considered incurable by local therapies (except Phase 2 Cohort 3)
- ECOG PS of ≤1
- Measurable disease according to RECIST v1.1
- Hgb ≥9 g/dL prior to initial dose

#### **Cohort-Specific Inclusion Criteria**

- HNSCC regardless of PD-L1 status (Phase 2 Cohort 1)
- HNSCC with a PD-L1 CPS ≥1 (Pre-expansion Safety Runin Cohort [if applicable] and Phase 2 Cohort 2)
- Histologically or cytologically confirmed locally advanced/mHNSCC regardless of PD-L1 status with at least 1 and no more than 2 lines of prior systemic anticancer therapy in the locally advanced/metastatic setting (Phase 2 Cohort 3)

CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; Hgb, hemoglobin; mHNSCC, metastatic HNSCC; PD-1, programmed death 1; RECIST, Response Evaluation Criteria in Solid Tumors.

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available. Visit clinicaltrials.gov for more information. Clinicaltrials.gov: NCT04854499

24



#### **Key Exclusion Criteria**

#### All Patients

 Active CNS disease (individuals with asymptomatic and stable, treated CNS lesions who have been off corticosteroids, radiation, or other CNS-directed therapy for at least 4 weeks are not considered active)

 History of (noninfectious) pneumonitis that required steroids or current pneumonitis

#### Pre-expansion Safety Run-in Cohort (if Applicable), and Phase 2 Cohorts 1 and 2

 Progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC

 Prior treatment with any of the following: anti–PD-1 or anti–PD-L1 checkpoint inhibitors, anti–cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitors

#### Phase 2 Cohorts 3

 Progressive disease within 6 months of completion of curatively intended systemic treatment for locally advanced/mHNSCC

Prior treatment with a taxane

#### *Continued on next page*

## *Continued from previous page*

#### Timeline with Key Assessments<sup>1,2</sup> Arm A: Magrolimab + pembrolizumab + platinum + 5-FU (randomized Phase 2 Cohort 1) Arm B: Pembrolizumab + platinum + 5-FU (randomized Phase 2 Cohort 1) Arm C: Magrolimab + zimberelimab + platinum + 5-FU (delayed randomized Phase 2 Cohort 1) • Blood phenotyping or genotyping, type and screen (ABO/Rh) and DAT Magrolimab + pembrolizumab Tumor biopsy (Phase 2 Cohort 2 [optional]) • Tumor imaging (CT/MRI/PET-CT) Magrolimab + docetaxel (randomized Phase 2 Cohort 3) 30-DAY WINDOW Cycle length Cycle Cycle Cycle Cycle Screening for all cohorts: 1 2 3 4+ 21 days DAY 1 DAY 1 DAY 1 DAY 1 CAN BE COLLECTED ANY TIME BETWEEN PRO assessments CYCLE 3 DAY 1 AND CYCLE 4 DAY 1 Tumor biopsy Q6W THROUGH Tumor imaging CYCLE 12, THEN Q9W THEREAFTER

ABO, any of the 4 blood groups A, B, AB, and O comprising the ABO system; CT, computed tomography; DAT, direct antiglobulin test; MRI, magnetic resonance imaging; PET, positron emission tomography; PRO, patient-reported outcome; Q6W, every 6 weeks; Q9W, every 9 weeks; Rh, Rhesus factor.

### Endpoints<sup>1,2</sup>

#### **Primary Endpoints**

- PFS, independent central review (Phase 2 Cohort 1, Arm A vs Arm B)
- ORR, investigator assessed (Phase 2 Cohorts 2 and 3)

- - PROs
- PK
- ADAs

ADA, antidrug antibody; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PK, pharmacokinetics.

#### References

- 1. Clinicaltrials.gov website. Accessed October 27, 2023. https://clinicaltrials.gov/ct2/show/NCT04854499
- 2. Data on file. Gilead Sciences, Inc.; 2022.

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available. Visit clinicaltrials.gov for more information. Clinicaltrials.gov: NCT04854499



#### **Secondary Endpoints Phase 2 Cohorts**

 PFS, independent central review (Phase 2 Cohort 1, Arm C vs Arm B)

ORR, independent central review

PFS, investigator assessed

DOR and OS

